Connect with us

JAMMU & KASHMIR

Make Tocilizumab available for COVID-19 patients: DAK to authorities | KNO

Published

on

kno news

Srinagar, July 28 (KNO): Doctors Association Kashmir (DAK) on Tuesday urged concerned authorities in Kashmir Valley to make life-saving drug Tocilizumab available for critically-ill COVID-19 patients. “The drug reduces the risk of death in seriously ill Covid-19 patients,” said DAK President and influenza expert Dr Nisar ul Hassan in a statement issued to the news agency—Kashmir News Observer (KNO). Quoting a study from the University of Michigan, he said COVID-19 patients on ventilators who received a single dose of Tocilizumab injection were 45 percent less likely to die compared to those who did not receive the drug. “Originally developed to treat rheumatoid arthritis, the drug combats the disease by quelling cytokine storm which is the hyperimmune response of the infected person to the virus,” Dr Nisar said. “Mortality in Covid-19 patients has been linked to the presence of the cytokine storm induced by the virus,” he said adding that “excessive production of cytokines leads to respiratory failure and widespread tissue damage resulting in multiorgan failure and death.” Dr Nisar said Tocilizumab suppresses the hyperimmune response by blocking receptor for a key cytokine known as interleukin-6 (IL-6) and improves survival rates and reduces mortality among COVID patients. “Recently Indian Council of Medical Research (ICMR) in its revised protocol has allowed usage of the drug for patients with progressively increasing oxygen requirements and in mechanically ventilated patients not improving despite the use of steroids,” he said. Dr Nisar said it is vitally important to know that there is no single magic bullet to treat the novel Coronavirus and several drugs in combination are needed to tackle the virus. “With the approval of several therapies, combination of them given at the right time gives a good result,” he said. “Apart from oxygen, moderate to severe patients are given steroids, remdesivir, convalescent plasma and Tocilizumab in various combinations,” he added. “Initially it was believed that deaths were happening because of poor oxygenation. Now we know that intravascular clotting can also lead to lung dysfunction and death. So heparin is given in Covid patients to prevent clotting,” said Dr Nisar—(KNO)

Trending

TOP STORIES6 hours ago

57-day Amarnath Yatra to commence on July 3, end on Aug 28: LG Sinha | KNO

TOP STORIES20 hours ago

Nasha Mukt Jammu Kashmir Abhiyaan: ‘Our neighbour’ funding terrorism through narcotics smuggling: LG Sinha | KNO

TOP STORIES20 hours ago

Local body polls in J&K unlikely in near future | KNO

TOP STORIES20 hours ago

‘Digital arrest’ is complete myth, says Crime Branch as AI-driven fraud rises in Kashmir | KNO

TOP STORIES20 hours ago

J&K Govt revamps GST framework | KNO

TOP STORIES20 hours ago

Govt directs SSSA rollout by May-2026 | KNO

TOP STORIES20 hours ago

1,222 out of 2,262 posts lying vacant at SKIMS Soura | KNO

TOP STORIES20 hours ago

Viral video pushes authorities to make new school building functional in Kulgam | KNO

TOP STORIES20 hours ago

After Baramulla, authorities roll out one way traffic system in Sopore | KNO

TOP STORIES20 hours ago

Pulwama’s Gundipora–Pahoo road in shambles months after floods | KNO

TOP STORIES20 hours ago

8 drug peddlers arrested, huge quantity of contraband substances seized: Police | KNO

TOP STORIES20 hours ago

IFL 2026: Real Kashmir FC look to break winless run | KNO

TOP STORIES20 hours ago

KCCI welcomes drug- free movement | KNO

TOP STORIES20 hours ago

CM Omar congratulates SKUAST-Kashmir on breakthrough in Morel Mushroom research | KNO

TOP STORIES20 hours ago

Div Com Kashmir chairs MDC Meeting on Traffic Management; Emphasizes on effective decongestion measures | KNO

TOP STORIES1 days ago

‘Don't Spare Guilty’: LG Sinha launches 100-day anti-drug drive | KNO

TOP STORIES1 days ago

J&K, Ladakh likely to face 8% power crunch this April | KNO

Copyright © 2021